Ables Iannone Moore & Associates Inc. Sells 1,424 Shares of Johnson & Johnson $JNJ

Key Points

• Ables Iannone Moore & Associates Inc. reduced its stake in Johnson & Johnson by 9.2% in Q2, holding a total of 14,057 shares after selling 1,424 shares, valued at approximately $2.15 million.
• EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson for over $10 million, reducing her ownership by 24.08%.
• UBS Group raised its price target for Johnson & Johnson from $180 to $190 with a "buy" rating, while other analysts provide a range of ratings reflecting a consensus of "Moderate Buy."

Ables Iannone Moore & Associates Inc. decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 9.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 14,057 shares of the company's stock after selling 1,424 shares during the quarter. Johnson & Johnson accounts for about 1.3% of Ables Iannone Moore & Associates Inc.'s investment portfolio, making the stock its 17th biggest position. Ables Iannone Moore & Associates Inc.'s holdings in Johnson & Johnson were worth $2,147,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of JNJ. Highline Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at approximately $47,000. 1248 Management LLC bought a new position in Johnson & Johnson in the first quarter worth approximately $48,000. von Borstel & Associates Inc. bought a new position in Johnson & Johnson in the first quarter worth approximately $49,000. Finally, Capital A Wealth Management LLC bought a new position in Johnson & Johnson in the fourth quarter worth approximately $50,000. Institutional investors own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. UBS Group increased their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research note on Thursday, July 17th. Guggenheim reissued a "neutral" rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price objective on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Stock Down 0.2%

Johnson & Johnson stock opened at $178.10 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The business has a fifty day moving average of $170.81 and a two-hundred day moving average of $161.29. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $428.93 billion, a P/E ratio of 19.05, a P/E/G ratio of 2.27 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the business earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.